BCPPs desiring an evidence-based focus on emerging areas of practice and contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who learn best from didactic presentations, are auditory and visual learners, and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.
Content
The Summit is an application-based continuing pharmacy education (CPE) activity designed to advance the knowledge and improve competency of participants through the delivery of evidence-based presentations on emerging areas of practice and contemporary issues in psychiatric pharmacy. This two-day, interactive, virtual conference provides knowledge and tools to improve the comprehensive care of patients with mental health disorders. The content is valuable to all psychiatric pharmacists regardless of the practice setting.
An application-based CPE activity requires that participants apply the information learned. In an application-based CPE activity, the learning objectives are written at a higher level in order to assess the learners’ ability to use the information that is learned, at the expected level of practice of Board Certified Psychiatric Pharmacists. The examination for this product often features cases requiring that the participant apply the principles learned through the presentations.
The Summit includes:
Online access to the recorded speakers' audio presentations synchronized with their slide presentations (presented live during the Virtual Summit, October 10-11, 2024).
For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online AAPP recertification examination.
Access to the AAPP testing center with exam submission due on or before July 10, 2025.
AAPP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access AAPP course materials online, you will need:
A modern web browser with JavaScript and cookies enabled: Chrome is strongly recommended,
or the latest version of Firefox or Safari.
A PDF reader: Chrome built-in, Firefox built-in, Acrobat
or FoxIt
An adequate device and Internet connection:
Processor: Dual-core 2Ghz or higher (Intel i3/i5/i7 or AMD equivalent);
Memory: 4 GB;
Storage: 5 GB available;
Internet speed: 4.0 Mbps (up/down)
AAPP web sites no longer fully support Microsoft Internet Explorer or Windows 8.1 and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Faculty Information
Audrey A. Abelleira, PharmD, BCPS, BCPP Michelle Krichbaum, PharmD, BCPP Christopher Nicholas, PhD John M. Allen, PharmD, BCPS, BCCCP, FCCM, FCCP Charlotte Rosalind Blease, BSc, MA, PhD Liz Frye, MD, MPH Daina L. Wells, PharmD, MBA, BCPP Jeff D. Gold, PharmD, BCPP Alexis Ritvo, MD, MPH
Medical Science Liaison, Neuropsychiatry Field Medical Team
Bristol Myers Squibb
Audrey Abelleira received her bachelor’s degree in biopsychology in 2014 and PharmD from Massachusetts College of Pharmacy in 2018. Following graduation she completed a PGY-1 pharmacy practice residency at Tufts Medicine’s MelroseWakefield Hospital in Melrose, MA and a PGY-2 psychiatric pharmacy residency at the Captain James A. Lovell Federal Health Care Center in North Chicago, IL. She is a board certified pharmacotherapy specialist and psychiatric pharmacist.
After completing residency Dr. Abelleira continued her clinical career as a mental health clinical pharmacist practitioner and clinical program manager, first at the VA Connecticut Healthcare System and then with the VA New England Clinical Resource Hub, providing care to veterans throughout New England. Her clinical practice was focused on integrating mental health and substance use disorders treatment into interdisciplinary chronic pain management teams. Her research interests included increasing access to medications for opioid use disorder, the intersection between chronic pain and psychiatric disorders, and optimizing virtual modalities for delivering interdisciplinary pain and mental health care.
Recently Dr. Abelleira has joined the neuropsychiatry field medical team at Bristol Myers Squibb as a medical science liaison focusing on novel therapies for severe mental illness.
Michelle Kirchbaum, PharmD, BCPP
Clinical Manager –Pain, Palliative Care and Opioid Stewardship
Baptist Health South Florida
Dr. Michelle Krichbaum graduated with a Bachelor’s degree from the University of Illinois and her PharmD from Belmont University. She completed her PGY1 at the Tuscaloosa VAMC and her PGY2 in Pain Management and Palliative Care at the West Palm Beach VAMC. She is currently a Clinical Manager for Pain Management, Palliative Care, and Opioid Stewardship at Baptist Health South Florida. Dr. Krichbaum is a past grant recipient for Interprofessional substance use disorder training, naloxone dispensing programs, and the creation of an outpatient substance use disorder clinic. She also serves as a member of the American Association of Psychiatric Pharmacists and in the advocacy committee for the Society of Pain and Palliative Care Pharmacists.
Christopher Nicholas, PhD
Associate Professor
University of Wisconsin School of Medicine and Public Health
Dr. Christopher Nicholas is Associate Professor with the University of Wisconsin Department of Family Medicine and Community Health and Program for Outreach, Research, Therapeutics, and Education in the Addictions (PROTEA). Dr. Nicholas’s research focuses on the clinical efficacy and therapeutic mechanisms of psychedelic and other psychoactive compounds for addiction and mental health. He is currently running two clinical trials examining psilocybin for methamphetamine use disorder and opioid use disorders and two psychedelic mechanistic studies examining the therapeutic role of memory salience and neuroplasticity. Dr. Nicholas currently is a site-PI for Beckley Psytech’s Phase 2 trial of 5-MeO-DMT for treatment resistant depression and previously served as a site-PI and study therapist on Lykos’s (formerly MPBC) Phase 3 multi-site clinical trials of the safety and efficacy of MDMA-assisted psychotherapy for PTSD. In addition to research, Dr. Nicholas provides addiction services for individuals living with chronic pain and HIV and is a clinical educator on psychedelic facilitation and implementation. Dr. Nicholas earned his Ph.D. in clinical psychology and neuroscience at the University of Tennessee; and completed his internship in health psychology and post-doctoral fellowship in aging and multi-modal neuroimaging at the William S. Middleton VA and the University of Wisconsin School of Medicine and Public Health.
John M. Allen, PharmD, BCPS, BCCCP, FCCM, FCCP
Clinical Associate Professor | Associate Dean for Accessibility, Belonging, and Community Health
University of Florida College of Pharmacy
John M. Allen, Pharm.D., BCPS, BCCCP, FCCM, FCCP is the Associate Dean for Accessibility, Belonging, and Community Health and a Clinical Associate Professor at the University of Florida College of Pharmacy (UFCOP). Under Allen’s leadership, UFCOP is a multiple-time recipient of the Insight into Diversity® Health Professions HEED Award, which recognizes health science colleges with demonstrable excellence in diversity, inclusion, and equity — one of only six pharmacy schools to be recognized during his leadership tenure. Allen graduated with his PharmD from Florida A&M University. He then completed a PGY-1 and PGY-2 Critical Care residencies at Tampa General Hospital. Allen is an NIH-funded researcher and his current research is exploring the evaluation of facilitators and barriers to equitable medication use in minoritized patients. Allen is an active member of multiple professional organizations, including currently serving as the Chair-Elect of the AACP Health Disparities and Cultural Competency Special Interest Group, and is an elected Fellow of the American College of Critical Care Medicine and the American College of Clinical Pharmacy (ACCP), respectively.
Charlotte Rosalind Blease, BSc, MA, PhD
Associate Professor
Uppsala University, Sweden
Dr Charlotte Blease is a philosopher and interdisciplinary health researcher. She is an Associate Professor at the Department of Women’s and Children’s Health, Uppsala University, Sweden and Research Affiliate at Digital Psychiatry, Beth Israel Deaconess Medical Center, Boston. Prior to this she was based at Harvard Medical School for five years and has held academic posts in Europe and the UK.
Blease has a diverse publication portfolio of more than 120 journal articles across digital health, evolutionary psychology, health psychology, philosophy, and ethics. Among her expertise is placebo studies, the role of artificial intelligence in undertaking clinical tasks, and online record access. In February 2024 her co-edited volume “The Nocebo Effect: When Words Make You Sick” was published with Mayo Clinic Press. She is also writing a book on AI and the psychology of the medical appointment for Yale University Press.
Liz Frye, MD, MPH
Vice Chair, Board of Directors, Street Medicine Institute
Dr. Liz Frye is an internationally recognized expert in street psychiatry and has worked in the field for the past 15 years. She is the founder and CEO of a new street psychiatry consulting service, STREETconsults. With her medical and public health background, Dr. Frye develops strategies for addressing mental health and substance use disorders among unhoused people at a population health level. She is passionate about recognizing and addressing trauma as both a driver of and result from unsheltered homelessness. Her consulting work focuses on demystifying psychiatry and offering practical approaches for primary care clinicians to address complex co-occurring mental health and substance use disorders in the street medicine setting.
Dr. Frye previously founded and directed Atlanta’s first street medicine program and worked to integrate behavioral health into the AHN Center for Inclusion Health’s services, including street medicine, in Pittsburgh, Pennsylvania. Dr. Frye holds a medical degree from the University of North Carolina and a Master’s in Public Health from Emory University. She completed residency and a Community Psychiatry and Public Health Fellowship at Emory. In her free time, Dr. Frye serves as the Vice Chair for the Street Medicine Institute’s Board of Directors and has led the Institute’s annual International Street Medicine Symposia since 2017.
Daina L. Wells, PharmD, MBA, BCPP
Assistant Chief Consultant, Education & Training
VA PBM Academic Detailing Services
Dr. Wells graduated from Butler University and went on to complete a PGY-1 Pharmacy Practice Residency at the VA in Houston, TX and PGY-2 Psychiatric Pharmacy Residency with Purdue University and Wishard Health Services in Indianapolis, IN. Dr. Wells completed her MBA in 2019 from St. Mary's College of California and is board certified in Psychiatric Pharmacy (BCPP). She started her career as a Mental Health Clinical Pharmacy Practitioner at the VA in Columbia, SC working in outpatient mental health. Then moved on to serve as an Academic Detailer for the VISN 21/22 Academic Detailing Pilot Program. In 2015, she became an Education & Training Clinical Program Manager for PBM Academic Detailing Services (ADS) supporting education, training, and program implementation across VHA. In 2022, Dr. Wells accepted the position of Assistant Chief Consultant, PBM, ADS Education and Training and works out of the Seattle, WA area.
For more than 10 years, Dr. Wells has served as lead author for national educational materials on mental health disorders including ADHD, Insomnia Disorder, Opioid Use Disorder, Stimulant Use Disorder, and Treatment-resistant Depression. She currently serves as Co-Chair for the VHA Office of Mental Health and Suicide Prevention ADHD Workgroup and a member of the “Ask the Expert – ADHD” email consultation service for VHA.
Jeff D. Gold, PharmD, BCPP
Psychiatric Clinical Pharmacy Practitioner
VA Rocky Mountain Regional Medical Center
Dr. Jeffrey Gold is a Psychiatric Clinical Pharmacy Practitioner and Psychopharmacologist with over 17 years of academic and clinical practice experience. His primary practice site is the Rocky Mountain Regional Veteran Affairs Medical Center in Colorado. He is a Senior Instructor for the University of Colorado at Denver Health Sciences Center School of Medicine Department of Psychiatry and School of Pharmacy. He earned his Doctor of Pharmacy degree at the University of Colorado Health Sciences Center and is a Board-Certified Psychiatric Pharmacotherapy Specialist.
Dr. Gold founded the Post-Graduate Year-Two Psychiatric Pharmacy Practice Residency at the Rocky Mountain Regional Veteran Affairs Medical Center and served as program director for ten years. He represents psychiatry as an advisory board member for the American Pharmacists Association (APhA) and is the past president of the former Colorado Psychiatric Pharmacy Association (CPPA). He was the first pharmacist in the state of Colorado to be granted a scope of practice to prescribe psychiatric medications and is licensed by the DEA to prescribe/manage controlled substances.
Dr. Gold is a direct care provider, consultant, and educator with an overall focus on providing clinical services to patients and instruction to healthcare trainees. He believes that psychotropic medications are started, adjusted, and stopped in the context of a relationship, and that is where the clinical work begins. Beyond this role, Dr. Gold serves the state of Colorado through active involvement in community-based program development and event planning around mental health and wellness, working in conjunction with various non-profit organizations, public school districts, and legal counsel. His areas of interest include trauma, psychotropic medication deprescribing, benzodiazepines, substance abuse, LGBTQ mental health, and the psychodynamic aspects of prescribing psychotropic medication.
Alexis Ritvo, MD, MPH
Assistant Professor of Psychiatry & Addiction Psychiatry Fellowship Director University of Colorado (CU) School of Medicine
Medical Director of the Alliance for Benzodiazepine Best Practices (501 c3)
Alexis Ritvo MD, MPH is a board-certified addiction psychiatrist. She is the Program Director for the Addiction Psychiatry Fellowship at the University of Colorado (CU) School of Medicine where she is an Assistant Professor of Psychiatry. She earned her Medical Degree and a Master’s in Public Health in Health Policy from Emory University in 2012. She completed her general psychiatry residency and addiction psychiatry fellowship at CU before joining faculty in 2017. Since then, she has been a supervising attending of general psychiatry residents in the CU Medicine Outpatient Psychiatry clinic where she directs a co-occurring disorder subspeciality clinic. Her growing interest in the safe prescribing and deprescribing of prescription benzodiazepines led her to co-found the Benzodiazepine Action Work Group with the Colorado Consortium for Prescription Drug Abuse in late 2020. In 2022, she became medical director for the national non-profit the Alliance for Benzodiazepines Best Practices. She is the current chair of the Education Committee for the American Association of Addiction Psychiatry. She has a passion for psychotherapy, teaching trainees, improving health systems, and advocacy.
Learning Objectives
Management of Attention-Deficit/Hyperactivity Disorder (ADHD): Considerations for Adults
Evaluate adult patients for attention-deficit/hyperactivity disorder (ADHD) using screening tools and rating scales.
Formulate treatment plans for adult patients with ADHD.
Identify appropriate stimulant medication alternatives during a medication shortage.
You and Me versus ChatGPT: Assessing the Role of Artificial Intelligence in Health Care
Examine how artificial intelligence programs can be used to enhance mental health care.
Describe the limitations and ethical concerns associated with using artificial intelligence programs in the provision of mental health care.
Assess infrastructure needs for integrating artificial intelligence into psychiatric clinical practice.
Benzodiazepine-Induced Neurological Dysfunction
Evaluate current literature that supports a diagnosis of benzodiazepine-induced neurological dysfunction (BIND).
Identify risk factors and/or prevention strategies for development of BIND.
Assess the impact of microaggressions on the provision of optimal patient care.
Propose strategies to address microaggressions in a clinical setting.
Chronic Pain and Depression/Anxiety: Addressing the Cycle
Describe the relationship between chronic pain and mental health conditions, such as depression and anxiety.
Interpret the scores from validated instruments for comorbid chronic pain and depression, anxiety, and/or suicidal ideation.
Develop an appropriate pharmacologic and/or non-pharmacologic treatment plan for patients experiencing comorbid chronic pain and depression/anxiety.
Managing Pain and Co-Occurring Opioid Disorder: Dispelling Myths to Improve Care
Evaluate the risks of undertreated pain for patients with co-occurring opioid use disorder.
Design a treatment plan to address co-occurring chronic pain and opioid use disorder.
Choose treatments for acute pain in individuals receiving medication for opioid use disorder.
Use of Psychedelics for the Treatment of Substance Use Disorders
Analyze evidence for psychedelics in the treatment of substance use disorders.
Describe best practices for psychedelic implementation into substance use disorder treatment.
Formulate a comprehensive treatment plan for patients undergoing psychedelic assisted therapy for a substance use disorder.
Street Medicine: Psychiatric Care for Individuals who are Unsheltered
Describe best practices of a street medicine team.
Assess the role of the health care team members, including psychiatric pharmacists, in street medicine teams.
Modify treatment regimens for individuals living unsheltered.
Continuing Education Credit and Disclosures
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.
The American Association of Psychiatric Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). This course is part of a 10 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.
AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
Marissa Cullen, PharmD, BCPP
Clinical Pharmacist
UPMC Western Psychiatric Hospital
Pittsburgh, PA
No Relevant Financial Relationships to Disclose
Beth DeJongh, PharmD, BCPS, BCPP
Director of Continuing Professional Development
American Association of Psychiatric Pharmacists
Lincoln, NE
No Relevant Financial Relationships to Disclose
Traci M. Dutton, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2 Psychiatric Pharmacy Residency
VA Tennessee Valley Healthcare System
Murfreesboro, TN
Employment: Tennessee Valley VA Healthcare System, Clinical Pharmacy Specialist - Mental Health, Member of VA PBM Educational Advisory Committee which
oversees Board Certification Study Groups
Megan J. Ehret, PharmD, MS, BCPP BCPP Program Director
Professor
University of Maryland
Baltimore, MD
External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Saladex Biomedical Consultant, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant
Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH
Jordan Haygood, PharmD, BCPP
Clinical Pharmacy Specialist - Psychiatry
Medical University of South Carolina
Charleston, SC
No Relevant Financial Relationships to Disclose
Courtney A. Iuppa, PharmD, BCPP
Clinical Pharmacy Manager & Residency Program Director
Center for Behavioral Medicine
Kansas City, MO
No Relevant Financial Relationships to Disclose
Archana R. Jhawar, PharmD, BCPP
Clinical Pharmacist
Jesse Brown VAMC/ UIC College of Pharmacy
Chicago, IL
No Relevant Financial Relationships to Disclose
Linda D. Logan, PharmD, BCACP, BCPP, BCPS
Public Service Associate
University of Georgia
Athens, GA
Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, UGA Mental Health Seed Grants for MHFA and Virtual Dementia Tour,
UGA College Pharmacy Ansel Fund
Jessica L. Mulhollan, PharmD, BCPP
Clinical Pharmacy Specialist, Substance Use Disorders and Mental Health Clinical Pharmacy Supervisor
Louis Stokes Cleveland VA Medical Center
Cleveland, OH
No Relevant Financial Relationships to Disclose
Melissa C. Palmer, PharmD, BCPP, BCPS
Clinical Pharmacy Specialist - Mental Health
Alaska VA Healthcare System
Anchorage, AK
No Relevant Financial Relationships to Disclose
Jake R. Peters, PharmD, BCPP, BCPS
Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry
Butler University College of Pharmacy/Indiana University Health
Indianapolis, IN
No Relevant Financial Relationships to Disclose
Sarah J. Popish, PharmD, BCPP
VA PBM Academic Detailing Services, Program Manager
Department of Veterans Affairs
Sarasota, FL
No Relevant Financial Relationships to Disclose
Alisha Striedel, PharmD, BCPP
Clinical Pharmacy Specialist - Mental Health
South Texas Veterans Health Care System
San Antonio, TX
No Relevant Financial Relationships to Disclose
Kara R. Wong, PharmD, BCPP Recertification Editorial Board Chair
Clinical Pharmacist Practitioner, Mental Health
Minneapolis VA Health Care System
Minneapolis, MN
No Relevant Financial Relationships to Disclose
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
AAPP websites use cookies to personalize and enhance your experience.
By continuing to use the site, you agree to this collection.
Learn more.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.
Beth DeJongh, PharmD, BCPS, BCPP
Kara R. Wong, PharmD, BCPP